Fisher Wallace Laboratories, the market leader in prescription wearable technology for the treatment of neuropsychiatric disorders, announces today the closing of a funding round that will provide the company with $2.5M of capital to pursue its growth strategy. The round was led by SHUFL Capital, a leading early-stage investor in the Sleep, Health, Fitness and Leisure sectors founded by British businessman and growth investor Simon Webster. The financing closes simultaneously as Fisher Wallace is announcing the launch of an equity crowdfunding campaign through StartEngine aimed to raise $1.9M. This latest round of financing follows the recent (October 2021) close of Fisher Wallace's first equity crowdfunding campaign that raised $4.7M.